Ophthalmic Drugs Market by Dispense Type, Disease Condition, Products, Dosage Form, Distribution - Global Forecast 2025-2030- Product Image

Sale

Ophthalmic Drugs Market by Dispense Type, Disease Condition, Products, Dosage Form, Distribution - Global Forecast 2025-2030

Report
193 Pages
October 2024
Region: Global
360iResearch™
ID: 4968753

UP TO €692EUR$697USD£574GBP OFF until Dec 31^st 2024

The Ophthalmic Drugs Market grew from USD 28.99 billion in 2023 to USD 30.56 billion in 2024. It is expected to continue growing at a CAGR of 5.86%, reaching USD 43.21 billion by 2030.

The scope of the ophthalmic drugs market encompasses pharmaceuticals used for treating eye disorders such as glaucoma, dry eye syndrome, retinal diseases, and infections. These drugs are critical in preserving vision and enhancing ocular health, catering to hospitals, clinics, and homecare settings. Necessity in this domain stems from an aging population increasing the incidence of eye diseases, heightened screen time leading to eye strain, and innovative drug delivery systems like ocular implants. End-use applications span across therapeutic, surgical, prescriptive, and over-the-counter scenarios, broadening market reach. Growth in this market is driven by rising prevalence of ophthalmic conditions, technological advancements in drug development, and expanding insurance coverage for eye care procedures. Additionally, increasing investment in R&D has opened potential opportunities, particularly in precision medicine and gene therapy for ocular disorders. To capitalize on these opportunities, companies should focus on collaborative research efforts and strategic partnerships to innovate new treatments, particularly targeting untapped markets in developing regions.

Challenges hindering growth include regulatory hurdles, high development costs, and complexities in drug delivery systems. Moreover, patient adherence to treatment regimens can be problematic, impacting long-term efficacy and market expansion. However, these limitations present innovation opportunities in personalized medicine, development of more efficient drug delivery mechanisms like nanotechnology, and digital health initiatives that incorporate telemedicine and mobile health applications for better patient engagement. Insight into the nature of the market suggests it is highly competitive and fragmented, with key players continuously seeking mergers and acquisitions to improve their foothold. Innovations such as biodegradable implants and biologics are among the promising areas for research and development, providing pathways for enhanced drug effectiveness and patient compliance, thereby driving market growth. By navigating these dynamics with strategic foresight, companies can ensure robust business growth and sustain competitive advantage in the ophthalmic drugs landscape.

Understanding Market Dynamics in the Ophthalmic Drugs Market

The Ophthalmic Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rise in the prevalence of ophthalmic disorders and indications globally
- Growing development combination therapies for the treatment of ophthalmicdisorders
- Increased awareness, treatment accessibility and drug availability
Market Restraints
- High development costs and time taking research and development of ophthalmic drugs
Market Opportunities
- Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
- Significant potential in ophthalmic biologics
Market Challenges
- Unmonitored side effects of ophthalmic drugs

Exploring Porter’s Five Forces for the Ophthalmic Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Ophthalmic Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Ophthalmic Drugs Market

External macro-environmental factors deeply influence the performance of the Ophthalmic Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Ophthalmic Drugs Market

The Ophthalmic Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Ophthalmic Drugs Market

The Ophthalmic Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Ophthalmic Drugs Market

The Ophthalmic Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, Coherus Biosciences, Inc., EyePoint Pharmaceuticals, Inc., Eyevensys, Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lupin Limited, Merck & Co., Nicox SA, Novaliq GmbH, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Ophthalmic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Dispense Type
- Over the Counter
- Prescription
Disease Condition
- Allergy
- Dry Eye Disorder
- Glaucoma
- Retinal Disorder
  - Diabetic Retinopathy
  - Dry Age-related Macular Degeneration
  - Wet Age-related Macular Degeneration
Products
- Capsules & Tablets
- Drops
- Gels
- Ointments
- Solutions & Suspensions
Dosage Form
- Liquid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Semisolid Ophthalmic Drug Forms
- Solid Ophthalmic Drug Forms
Distribution
- Drug Stores
- Hospital Pharmacies
- Online Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the prevalence of ophthalmic disorders and indications globally
5.1.1.2. Growing development combination therapies for the treatment of ophthalmic
disorders
5.1.1.3. Increased awareness, treatment accessibility and drug availability
5.1.2. Restraints
5.1.2.1. High development costs and time taking research and development of ophthalmic drugs
5.1.3. Opportunities
5.1.3.1. Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
5.1.3.2. Significant potential in ophthalmic biologics
5.1.4. Challenges
5.1.4.1. Unmonitored side effects of ophthalmic drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Ophthalmic Drugs Market, by Dispense Type

6.1. Introduction
6.2. Over the Counter
6.3. Prescription

7. Ophthalmic Drugs Market, by Disease Condition

7.1. Introduction
7.2. Allergy
7.3. Dry Eye Disorder
7.4. Glaucoma
7.5. Retinal Disorder
7.5.1. Diabetic Retinopathy
7.5.2. Dry Age-related Macular Degeneration
7.5.3. Wet Age-related Macular Degeneration

8. Ophthalmic Drugs Market, by Products

8.1. Introduction
8.2. Capsules & Tablets
8.3. Drops
8.4. Gels
8.5. Ointments
8.6. Solutions & Suspensions

9. Ophthalmic Drugs Market, by Dosage Form

9.1. Introduction
9.2. Liquid Ophthalmic Drug Forms
9.3. Multicompartment Drug Delivery Systems
9.4. Semisolid Ophthalmic Drug Forms
9.5. Solid Ophthalmic Drug Forms

10. Ophthalmic Drugs Market, by Distribution

10.1. Introduction
10.2. Drug Stores
10.3. Hospital Pharmacies
10.4. Online Pharmacies

11. Americas Ophthalmic Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Ophthalmic Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Ophthalmic Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Bausch + Lomb Plans to Acquire XIIDRA
14.3.2. FDA Approves Novaliq’s Cyclosporine Ophthalmic Solution For Treatment Of Dry Eye Disease
14.3.3. Eyenovia and Formosa Partner For New Ophthalmic Therapeutics
14.3.4. Re-Vana Reels in USD 12M To Develop Sustained-Release Eye Implants
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OPHTHALMIC DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. OPHTHALMIC DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY LIQUID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SEMISOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 53. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 55. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 56. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 57. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 62. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 64. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 85. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 86. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 87. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 88. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 89. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 91. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 92. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 93. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 94. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 103. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 104. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 106. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 107. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 140. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 142. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 143. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 144. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 159. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 161. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 162. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 164. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 165. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 167. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 168. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 170. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 174. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 176. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 179. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 182. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 185. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 186. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 194. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 196. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 197. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 198. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 212. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 216. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 217. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 218. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 220. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 221. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 222. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 223. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 224. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 226. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 227. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 228. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 248. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 249. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 251. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 266. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 267. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 269. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 270. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 271. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 284. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 285. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Ophthalmic Drugs Market, which are profiled in this report, include:

Abbott Laboratories
Alcon Vision LLC
Allergan PLC by AbbVie Inc.
Apotex Inc.
Bausch Health Companies Inc.
Bayer AG
Carl Zeiss AG
Coherus Biosciences, Inc.
EyePoint Pharmaceuticals, Inc.
Eyevensys
Genentech, Inc.
Johnson & Johnson Service, Inc.
Kodiak Sciences Inc.
Lupin Limited
Merck & Co.
Nicox SA
Novaliq GmbH
Novartis AG
Ocular Therapeutix, Inc.
OCuSOFT Inc.
Pfizer Inc.
Recipharm AB
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Somerset Pharma, LLC.
Sun Pharmaceutical Industries, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	193
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 30.56 Billion
Forecasted Market Value ( USD ) by 2030	$ 43.21 Billion
Compound Annual Growth Rate	5.8%
Regions Covered	Global
No. of Companies Mentioned	31

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3518EUR$3,545USD£2,919GBP €3909EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6224EUR$6,272USD£5,164GBP €6915EUR$6,969USD£5,738GBP

Understanding Market Dynamics in the Ophthalmic Drugs Market

Exploring Porter’s Five Forces for the Ophthalmic Drugs Market

Applying PESTLE Analysis to the Ophthalmic Drugs Market

Analyzing Market Share in the Ophthalmic Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Ophthalmic Drugs Market

Strategic Recommendations for Success in the Ophthalmic Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class (Steroidal drugs, Anti-VEGF Agents), Disease, Dosage Form, Route of Administration, Product Type, Product, Region, and Segment Forecasts, 2024-2030

Ophthalmic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2024-2032

Ophthalmic Drugs Global Market Report 2024

Ophthalmic Drug Delivery System Market by Technology, Production Technology, Material, Delivery Route - Global Forecast 2025-2030